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Drug repurposing is a technique for reusing an existing drug to treat another ailment. It is common knowledge that nearly 
all medicines used in human therapy have more than one target impact in addition to their primary action. The present work 
is aimed to repurpose existing antiviral drugs for dengue disease. A molecular docking study is performed with the DENVE 
protein for the identification of the suitable drug candidate which acts in the fusion process. For all repurposed drugs at the 
active site of DENVE, molecular docking experiments were performed using CLC Drug Discovery Workbench Software 
(PDB ID: 1OKE). The relative binding modes and the affinities of all the selected drugs were predicted and compared with 
the co-crystallized n-octyl-beta-D-glucopyranoside (βOG). The Daclatasvir (Score-53.52) makes hydrogen bonds with 
ALA50 and THY48. According to the docking score evaluation, the entire drug candidates had docking result ranging from 
−32.15 to −53.52. Among the drugs tested the two drugs namely Daclatasvir and Famciclovir have been identified as HITS 
for combating DENVE protein. 
Keywords: Dengue virus, Drug repurposing, Envelope protein, Hinge region, Molecular docking, n-Octyl-beta-D-
glucopyranoside (βOG) 
Dengue viral disease, a mosquito-borne viral pathogen 
dengue virus (DENV), has been a significant public 
health issue in recent decades. Dengue is currently 
present in 119 countries throughout the world.  
Fifty-hundred (50-100) million people in tropical and 
subtropical countries are infected with DENV per year, 
resulting in approximately 5,000,000 existence diseases 
and 25,000 deaths. DENV belongs to the Flavivirus 
family of the Flaviviridae family. The genome of 
flavivirus consists of approximately 11,000 base  
pairs (bp) of RNA, which translate into three structural 
proteins, including membrane [M], capsid [C],  
& envelope [E], and 7 non-structural proteins NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, and NS5. The viral 
envelope consists of two transmembrane proteins,  
the envelope (E) and the premembrane (prM). E binds 
directly to cellular receptors and facilitates viral and  
cell membrane fusion through viral cell penetration and 
is the primary site for antibody neutralization
1
. 
Interruption of virus replication at the initial point of 
contact
2
 can be an attractive technique. Membrane 
fusion is the main molecular event that occurs during the 
viral entrance into the host cell
3
. The envelope protein 
(E) constitutes the main component of viral surface.  
It is very important for fusion process through which  
the virus merges into host receptor
4
. Among the  
three domains DI, DII, and DIII present in the E protein, 
the migration of domains I and II in the hinge  
region promotes the mechanism of fusion. 
Rearrangement and/or conformational changes in the 




Keeping the above facts, the present work is aimed to 
repurpose existing antiviral drugs for dengue disease. A 
molecular docking study is performed with the DENVE 
protein for the identification of the drug candidate which 
acts in the fusion process. The drugs obstructing the 
βOG pocket have thought to interact with 
conformational changes within the envelope protein that 
are basic for configuration. The following seven 
medicines were chosen based on their mechanism of 
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nucleic acid synthesis; Lamivudine and Zidovudine 
inhibit reverse transcriptase. Famciclovir and 
Ganciclovir are DNA polymerase inhibitors; Oseltamivir 
inhibits progeny virus release and Daclatasvir is a non-
nucleoside polymerase inhibitor. 
 
Materials and Methods 
Molecular docking research 
Molecular docking investigations were conducted 
using CLC Drug Discovery Workbench Tools to 
provide exact proof of optimized validation for both 
ligand (selected drug candidates) and their target 
receptor DENVE protein to form a stable compound. 
The chemical structures of the selected drugs have 
been depicted in (Suppl. Table S1). Dengue virus type 
2 envelope proteins (E) PDB ID: 1OKE were retrieved 




Preparation of ligands 
Ligands (selected drug candidates) were prepared 
using the SPARTAN'14 software kit. Their molecular 
structures have been defined using the baseline 
standard of DFT/B3LYP/6‐31 G9. 
 
Molecular docking simulation 
CLC Drug Discovery Workbench tools were used 
in a molecular docking research to generate exact 
estimations of the optimal configuration for ligands 
and their target receptor protein, as well as the 
resultant complexity. The docking modeling was 
performed in according to the docking procedure, 
which includes the stages are: In the molecule project, 
create a binding site and a binding pocket; dock 
ligands entered into the molecule table; and evaluate 
the docking results. Redocking was utilized to check 
the docking techniques and requirements employed in 
order to verify the dependability of ligand 
configurations and locations obtained from molecular 
docking investigations. Docking findings and 2D 
amino acid interactions predict drug binding affinities, 





Calculation of molecular properties 
Molinspiration batch property calculation toolkitmib 
Molinspiration is a Java-written toolkit for 
molecular processing and property estimation. The 
toolkit could be used in batch mode to handle a huge 
amount of molecules (approximately 10,000 
molecules per min) or can be reached directly from 
your intranet via a web interface.  
Molecular properties such as LogP (octanol/water 
partition co-efficient), molecular polar surface area, 
molecular volume, rule of 5, and number of rotatable 
bonds-nrotb have been calculated using Molinspiration 
software
11-15
 and depicted in (Table 1). 
 
Molecular Dynamics Study 
CABS-flex-2.0 was used to perform the molecular 
dynamics analysis. It is a rapid modeling technique for 
protein structure flexibility simulation. It is predicted 
on the CABS model, which is a well-known coarse-
grained protein modeling method. This work provides 
the consensus view of protein near-native dynamics 
derived from ten-nanosecond MD simulations is 
presented here (explicit water, all-atom, for all protein 
metafolds using the four most popular force-fields). 
The CABS model utilizes stochastic dynamics  
(a Monte Carlo technique) and a knowledge-based 
force-field that is not biased toward a simulated protein's 
natural structure. Combining the CABS method with  
all-atom MD offers an efficient method for long-term 
multiple stage protein systems of molecular modeling 
with mechanistic precision because CABS-based 
interactions (dynamics) enable for the simulation of the 





Cell lines and culture medium 
Vero (African Green Monkey, Kidney) cell lines 
used were collected from the National Cell Science 
Table 1 — Selected drug candidates and their physicochemical properties 
Compounds miLogP TPS natoms MW Nviolations nrotb Volume 
Acyclovir −1.61 119.06 16 225.21 0 4 187.75 
Lamivudine −1.09 90.38 15 229.26 0 2 187.07 
Baloxavir 2.44 75.01 34 483.50 0 1 389.09 
Daclatasvir 7.77 174.65 54 738.89 1 13 683.66 
Famciclovir 0.48 122.24 23 321.34 0 9 285.31 
Ganciclovir −2.17 139.29 18 255.23 0 5 212.60 
Stavudine −0.54 84.33 16 224.22 0 2 192.96 
Zidovudine −0.10 134.08 19 267.25 0 3 224.06 
Oseltamivir 0.85 90.66 22 312.41 0 8 309.60 




Centre, Pune, India. Cells were grown in Dulbecco's 
middle Eagle medium (DMEM) supported by Cells 
mature with trypsin, EDTA (197.16 mg/L), glutamine 
(0.5 g/L) and PBS (1L) in Dulbecco's middle Eagle 
medium (DMEM) assisted by Fetal Calf Serum and 
the cells are kept in the CO2 incubator at 37°C.  
This medium was used in the subculture for adherent 
cell use. The supernatant was withdrawn and the 
mixture was added and incubated with 10 mL  
of trypsin/EDTA. In the flask, 10 mL of DMEM  
was applied and passed to the centrifuge. Cells  
then spun for 5-7 min at 1300-1500 rpm. The in vitro 
Cytotoxicity assay was performed according to  




MTT antiviral assay 
The highly sensitive in vitro antiviral compound 
evaluation approach emphasizes on the 
spectrophotometrical analysis of the viability of 
pathogen and longer independent cells by lowering in 
situ MTT tetrazolium pigment. Mitochondrial cells 
secrete MTT yellow water-soluble pigment to soluble 
purple, non - soluble formazan in viable cells. At 
490/650 nm, the quantity of the formazan compound 
present from each well of the microtitre plate is 
spectrophotometrically identified. The toxic effects of 
different test compounds to host cells were evaluated 
in a certain microtitre plate simultaneously
18
. The 
medium was extracted after a 24 h incubation time. 
We introduced HSV-1 & II at a dosage of 100 TCID50 
for 2 h in order to guarantee that the virus attached to 
the cell. The medium was removed after a 24 h 
incubation period. In order to guarantee that the virus 
was attached to the cell, 100 TCID50 of HSV-1 and 
HSV-II was administered for 2 h. A compound 
growth average solution was added to the cells after  
2 h of cleaning with PBS. As cell control, merely  
100 μL of medium was incorporated and 100 μL of 
100 TCID50 doses were added as virus control. The 
supernatant was removed after three days of 
incubation and 50 mL of MTT solution (2 mg/mL) 
was applied for 4 h at 37°C to each well. Thus, to 
disperse the crystals of formazan, 100 μL of dimethyl 
sulphoxide (DMSO) was added among each well. The 
colour response in an electronic micro plate reader 
was analyzed at 490 nm after vigorously shaking the 
plates for ten min to remove the crystals. The 
untreated control was randomly set at 100%. 
 
Larvicidal Bioassay 
Larvicidal activity was determined in Aedes 
aegypti larvae of the third instar using WHO 
standards with slight changes. In triplicate, the tested 
compounds had been combined with 50 mL of 
dechlorinated distilled water and fifty five larvae of 
Aedes aegypti breeds tested at different 
concentrations from 25-100 g/mL. In a 3:1 ratio, the 
larvae were fed dry yeast powder. Single vessel with 
no drug suspension was utilized as a control. The 
number (amount) of dead larvae was counted after 24, 
48 and 72 h. Infectious drugs were produced and 
more than half of the larvae were killed
19
. The 
larvicidal efficacy of the repurposed drugs towards 
Aedes aegypti was determined by varying drug 
solution concentrations. The affected larvae then 
examined under a stereo zoom microscope after 72 h 
for each proportion (concentration). 
 
Results 
In order to produce a stable compound, molecular 
docking studies were performed on both drug 
candidates (as ligands) and their target receptor 
protein. The protein-ligand combination is based on 
the protein data bank structure of n-octyl-beta-D-
glucopyranoside with dengue virus E protein (PDB 
ID: 1OKE). Following the import and processing of 
the protein receptor file from the protein data bank, 
the next step was to search for the binding pockets 
and binding site. The reference ligand n-Octyl-beta-
D-glucopyranoside was utilized to compare treatment 
candidates and docking findings. The search for the 
ligand-binding mode was conducted inside the 
volume of the binding site. Binding pockets have  
been used to direct molecular docking of ligand.  
The binding domain (site) and docking position of  
co-crystallized n-Octyl--D-glucopyranoside interfacing 
with amino acid residues are depicted in (Supplementary 
Table S2) and the binding pocket are represented. The 
docking result, interacting group, and hydrophobic 
interactions and hydrogen bonds formed by the amino 
acids of group interaction atoms are all depicted  
in (Table 2). Daclatasvir (Score-53.52) makes 2 
hydrogen bonds with the ALA50 and THY48. 
Docking result assessments revealed that all 
pharmaceutical entities had docking scores ranging 
from-32.15 to-53.52. The drug-likeness of selected 
drug candidates was ascertained by evaluating the 
physicochemical properties using mol inspiration 
toolkit and the outcomes were tabulated in (Table 1). 
The outcomes revealed that all have drug-like 
properties. 
The highly constructive conformation, posture, and 
favourable bonded complexes formed by receptor 




ligand interaction were employed as inputs for the 
drug Daclatasvir in Molecular dynamics simulation 
(MD) utilizing CABS flex 2.0. The optimized protein  
was then subjected to a rapid simulation (dynamic) of 
structural versatility by using the CAB-flex 2.0 server 
and a random number generation seed of 4956, with 
all other parameters set to default. The server-
analyzed protein's contact map and root-mean-square 
fluctuations (RMSFs) were acquired. The RMSF 
values of each receptor-ligand complex were plotted 
to see how the drugs affected structural stability and 
integrity. The RMSF quantifies of the average 
movement of atoms or groups of atoms in relation to 
the corresponding structure (configuration). The 
overlapping of the configuration and connection map 
of ten models of versatility computation of DENVE 
protein (1OKE) Daclatasvir complex was shown in 
(Fig. 1), respectively, to determine whether a structure 
is reliable over the time-scale of the computations 
(simulations) or whether it is differing from the early 
(initial) coordinates. The active site amino acid 
sequence was extrapolated using the RMSF. (Fig. 2) 
revealed that all of the catalytic residues in the 
DENVE protein (1OKE) Daclatasvir combination 
were stable. 
 
In vitro cytotoxicity assay 
HSV-1 and HSV-2 viruses were tested for antiviral 
activity. For HSV-1 and HSV-2 viruses, a virus 
concentration of 100 TCID50 was employed. When 
compared to Famciclovir (58.08 percent ) and a 
selectivity index of 5.11 against HSV-1 virus, the 
medication Daclatasvir demonstrated a good 
percentage of cell protection (74.45%) and a 
selectivity index (CC50/IC50) of 13.33. When 
compared to Famciclovir (43.45%) and a selectivity 
 
 
Fig. 1 — The CAB-flex 2.0 server provided a contact map of 
superimposition of the top ten simulated structures of 1OKE-
Daclatasavir 
Table 2 — Docking parameters for the selected compounds 
Compounds Canonical SMILES Score HB Metal Int.ac Steric Int.ac Ligand config RMSD 
Acyclovir C1=NC2=C (N1COCCO) N=C (NC2=O) N −36.14 −2.00 0.00 −34.95 0.81 91.84 
Lamivudine C1C (OC (S1) CO) N2C=CC (=NC2=O) N −39.31 −5.95 0.00 −34.10 0.74 93.65 
Baloxavir C1COCC2N1C (=O) C3=C(C (=O) C=CN3N2 
C4C5=C (CSC6=C C=CC=C46) C (=C(C=C5) 
F)F)O 
−33.05 0.00 0.00 −42.94 9.89 93.26 
Daclatasvir CC(C) C(C (=O) N1CCCC1C2=NC=C (N2) 
C3=CC=C(C=C3) C4=CC=C(C=C4) C5=CN=C 
(N5) C6CCCN6C (=O) C(C(C) C) NC (= O) 
OC)NC (=O) OC 
−52.77 −7.63 0.00 −58.89 14.74 85.54 
Famciclovir CC (=O) OCC (CCN1C=NC2=CN=C (N=C21)N) 
COC (=O) C 
−50.29 0.00 0.00 −56.55 6.26 92.21 
Ganciclovir C1=NC2=C (N1COC (CO) CO) N=C (NC2=O) N −40.82 −11.23 0.00 −33.23 3.63 94.49 
Stavudine CC1=CN(C (=O) NC1=O) C2C=CC (O2) CO −37.34 −0.00 0.00 −35.95 0.61 92.51 
Zidovudine CC1=CN(C (=O) NC1=O) C2CC(C (O2) CO) −40.67 −6.72 0.00 −35.30 1.35 95.17 
Oseltamivir CCC (CC) OC1C=C (CC (C1NC (=O) C) N) −43.45 −5.83 0.00 −41.67 4.05 94.94 
N-octyl-β-D-
glucopyranoside 
CCCCCCCCOC1C(C(C(C (O1) CO) O) O) O −53.58 −18.94 0.00 −39.59 5.18 91.34 




index of 3.85, Daclatasvir demonstrated efficacy 
against HSV-2 virus with a percent cell protection of 
(77.25%) and a selectivity index of 15.44. The 
findings indicate that the Daclatasvir and Famciclovir 
demonstrated efficacy against both the viruses  
and more specifically drug Daclatasvir when 
compared to Famciclovir. All the results were 
tabulated in (Tables 3-5). 
The larval growth (mortality) of the selected 
designed ligands was investigated to understand the 
association among ligands growth rate and larvae 
mortality. The LC50 and LC90 for the highest larvicidal 
activity were identified over the 72 h exposure period. 
Even after 24, 48, and 72 h of testing, Daclatasvir 
demonstrated significant larvicidal efficacy at low 
dosages (Table 6). 
Mortality was determined after 24, 48, and 72 h of 
exposure using varied concentrations. Concentration 
and exposure duration have an effect on the death 
rate. Observing Daclatasvir therapy at extremely low 
concentrations for 24 and 48 h, on the other hand, 
resulted in the greatest morbidity range. Famciclovir 
demonstrated modest mortality (morbidity) in both 
the 24, 48, and 72 h exposure periods, although it 
impeded larval growth at the early pupal stage. Some 
damage may occur at the cellular level (Fig. 3). 
 
Discussion 
In silico molecular docking simulations have been 
conducted to position all selected drugs at the desired 
binding site of the DENVE protein receptor, to 
estimate binding affinities, binding modes, and 
ligands orientation, correlating with co-crystallized n-
Octyl-β-D-glucopyranoside. Docking results have 
shown that all molecules have strong docking scores. 
The results discussed in this paper illustrate the 
significance of the molecular docking approach in 
designing and producing novel bioactive compounds. 
The prediction of the binding affinity of the novel 
compound (ligand) to the selected target 
(enzyme/protein) is a key factor in the design of the 
new drug. Among the drugs tested two drugs namely 
Daclatasvir and Famciclovir have been identified as 
HITS for combating DENVE protein. The in silico 
study is supported by the in vitro screening in which 
both the compounds are effective against HSV-1 & 2 
and more precisely the Daclatasvir compound relative 
to Famciclovir. The larvicidal activity of Daclatasvir 
and Famciclovir was measured by LC50 and LC90 
values. After 24, 48, and 72 h of exposure, 
Daclatasvir had substantial larvicidal efficacy at low 
concentrations.  
Drug repurposing has been used by a variety of 
organizations to find effective therapies for dengue 
disease. Methods used in these studies required 
repositioning of medications based on scientific 




Fig. 2- The CAB-flex 2.0 server provided the root-mean-square fluctuation (RMSF) of atoms in the 1OKE-Daclatasvir complex 
Table 3 — Cytotoxicity studies 
Sample CC50 µg/mL 
Daclatasvir 208.21 ± 8.22 
Famciclovir 195.01 ± 7.49 
Values are the mean ± standard deviation of three different 
experiments 





Table 4 — Antiviral activity of extracts against HSV-1 and HSV-2 virus at 100 TCID50 (50% Tissue culture infectivity dose) 
Antiviral activity of HSV-1  Antiviral activity of HSV-2 









50 25.55 74.45 50 22.75 77.25 
25 31.25 68.75 25 29.45 70.55 
12.5 53.85 46.15 12.5 41.45 58.55 
6.25 85.35 14.65 6.25 75.95 24.05 
Famciclovir 
50 41.92 58.08 50 56.55 43.45 
25 53.24 46.76 25 62.25 37.75 
12.5 78.75 21.25 12.5 75.45 24.55 
6.25 89.65 10.35 6.25 86.85 13.15 
 
Table 5 — Anti-HSV-1 and HSV-2 activity in Vero cells 
 HSV-1  HSV-2 
Treatment IC50 μg/mL CC50 μg/mL IC50 μg/mL CC50 μg/mL 
Daclatasvir 15.60  ± 3.25 208.31 ± 8.22 3.49 ± 2.79 208.31 ± 8.22 
Famciclovir 38.09 ± 5.63 195.01 ± 7.49 50.56 ± 3.55 195.01 ± 7.49 
Values are the mean ± standard deviation of three different experiments 
 
Table 6 — Larvicidal activity of the compounds 
Sample Time (Hrs) LC50 (ppm) LCL-UCL (ppm) LC90 (ppm) Intercept Slope X
2 value P-value 
 
Daclatasvir 
24 80.040 058.601-120.148 105.111 −2.410 0.014 0.411 0.918 
48 61.123 081.131-178.121 92.240 −1.214 0.010 0.341 0.968 
72 40.241 021.710-111.120 75.216 −1.001 0.012 0.518 0.895 
 
Acyclovir 
24 135.625 062.123-165.213 242.124 −1.131 0.010 1.112 0.810 
48 100.124 050.719-111.912 158.186 −1.522 0.014 0.934 0.791 
72 60.731 010.114-089.127 134.013 −1.551 0.020 0.821 0.758 
 
Lamivudine 
24 142.182 092.212-168.362 275.182 −2.612 0.016 1.793 0.651 
48 129.112 080.118-139.260 231.320 −1.827 0.013 0.342 0.827 
72 70.212 031.261-110.501 150.168 −1.316 0.011 0.425 0.816 
 
Baloxavir 
24 198.218 142.084-218.424 292.123 −2.810 0.015 1.812 0.589 
48 168.524 118.261-205.605 269.912 −1.912 0.012 0.418 0.916 
72 82.418 069.521-154.512 171.225 −1.461 0.010 0.492 0.892 
 
Famciclovir 
24 100.180 80.152-252.190 335.218 −2.425 0.015 1.325 0.783 
48 89.252 68.634-181.125 310.112 −2.004 0.011 1.632 0.758 
72 49.112 052.362-98.218 218.427 −1.628 0.013 1.682 0.732 
 
Ganciclovir 
24 205.127 158.218-242.128 348.810 −2.618 0.014 1.795 0.621 
48 152.412 131.810-201.425 321.412 −1.571 0.009 0.301 0.894 
72 89.235 060.512-128.120 200.201 −1.308 0.010 0.412 0.858 
 
Stavudine 
24 220.120 182.812-232.416 323.127 −2.810 0.013 0.420 0.924 
48 132.321 094.231-178.123 258.410 −1.832 0.011 0.389 0.954 
72 78.524 054.712-101.221 912.613 −1.243 0.010 0.510 0.892 
 
Zidovudine 
24 234.201 205.712-525.812 372.113 −2.149 0.010 0.628 0.852 
48 192.431 183.914-298.482 276.041 −2.523 0.012 0.424 0.912 
72 101.898 085.143-184.630 225.510 −1.245 0.011 0.401 0.928 
 
Oseltavir 
24 248.641 223.810-432.120 350.123 −2.589 0.014 1.324 0.782 
48 221.425 171.123-284.182 312.241 −2.034 0.011 1123 0.842 
72 138.520 175.178-175.281 228.417 −1.768 0.013 0.641 0.923 






Fig. 3- Larvicidal activity of Daclatasvir & Famciclovir against Aedes aegypti 
 













dengue infections. In addition, Chen et al.
25
 examined 
the repurposing of a pharmacologically active 
compound database (LOPAC1280) using a Huh-7 cell 
screening technique and comprised three compounds,  
fluoxetine hydrochloride, salmeterol xinafoate, and N-
desmethylclozapine as a dengue virus. The presence 
of imidazole and pyrrolidines moieties in Daclatasvir 
and the presence of purine moiety in Famciclovir may 
play a significant role in improved binding affinity 2D 
interactions towards the DENVE and HSV-1&2. In 
Daclatasvir, the increased binding affinity may be due 
to the presence of C2-symmetrical configuration with 
two fractions of imidazole rings connected by an 
aromatic bond and the increased in vitro antiviral 
activity may be due to the presence of non-symmetry 
as well as blender aromaticity
26
. The pyrrolidine rings 
with methyl substituent may be the reason for the 
increased hydrophobicity
27
. Likewise, in Famciclovir 
the alkyl side chains at the 2-position of the purine 
frame may be the reason for the increased binding 
affinity
28
. The study was further validated by 
molecular dynamics study. Daclatasvir, shown good 
binding affinity towards DENVE protein (1OKE) 
may be considered as potential hits. Overall, this 
study concludes that Daclatasvir as potent drug for 
biologically controlling Aedes aegypti. However, 
further preclinical studies can be done for establishing 
the proof. 
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